KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Non Operating Income (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Non Operating Income for 17 consecutive years, with $134.0 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 12.99% to $134.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $548.0 million through Dec 2025, up 45.74% year-over-year, with the annual reading at $548.0 million for FY2025, 45.74% up from the prior year.
  • Non Operating Income hit $134.0 million in Q4 2025 for Abbott Laboratories, down from $150.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $176.0 million in Q2 2023 to a low of -$10.0 million in Q2 2024.
  • Historically, Non Operating Income has averaged $100.0 million across 5 years, with a median of $101.0 million in 2022.
  • Biggest five-year swings in Non Operating Income: skyrocketed 6000.0% in 2021 and later plummeted 105.68% in 2024.
  • Year by year, Non Operating Income stood at $63.0 million in 2021, then rose by 7.94% to $68.0 million in 2022, then skyrocketed by 60.29% to $109.0 million in 2023, then skyrocketed by 41.28% to $154.0 million in 2024, then fell by 12.99% to $134.0 million in 2025.
  • Business Quant data shows Non Operating Income for ABT at $134.0 million in Q4 2025, $150.0 million in Q3 2025, and $137.0 million in Q2 2025.